Cannabinoids and sleep quality

In a systematic review and meta-analysis of randomized cannabinoid-versus-placebo studies involving 6 trials with 1,077 adults with or without insomnia or poor sleep, researchers did not detect a difference in pooled subjective sleep quality in cbd-only randomized trials following varied across included trials over varied across included trials. The recorded comparator was placebo. ¹

Recorded result: CBD-only pooled effect SMD 0.13 (95% CI -0.38 to 0.65; P=.61), not statistically significant.

In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers reported fewer nighttime awakenings following 20 mg CBN over 7 nights. The recorded comparator was placebo. ²

In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers reported lower overall sleep disturbance following 20 mg CBN over 7 nights. The recorded comparator was placebo. ²

In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers did not detect a difference in sleep onset latency following 20 mg CBN over 7 nights. The recorded comparator was placebo. ²

In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers did not detect a difference in wake after sleep onset following 20 mg CBN over 7 nights. The recorded comparator was placebo. ²

In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers did not detect a difference in daytime fatigue following 20 mg CBN over 7 nights. The recorded comparator was placebo. ²

In a double-blind randomized placebo-controlled multi-arm trial involving 293 adults with self-rated poor or very poor sleep quality, researchers did not detect a difference in augmentation of cbn sleep effects following 20 mg CBN with 10 mg, 20 mg, or 100 mg CBD nightly by the not stated in the PubMed abstract route over 7 nights. The recorded comparator was 20 mg CBN alone and placebo. ²

Recorded result: Adding CBD did not positively augment the CBN treatment effects.

In a decentralized randomized double-blind placebo-controlled trial, researchers reported lower overall sleep disturbance following 25 mg, 50 mg, or 100 mg oral CBN formulation. The recorded comparator was placebo and 4 mg melatonin. ³

In a decentralized randomized double-blind placebo-controlled trial, researchers did not detect a difference in side effect frequency following 25 mg, 50 mg, or 100 mg oral CBN formulation. The recorded comparator was placebo. ³

In a randomized placebo-controlled crossover pilot trial involving 20 adults with DSM-5 insomnia disorder, researchers reported a decrease in total sleep time after an acute THC-CBD dose following 10 mg THC and 200 mg CBD once by the oral route over single study night. The recorded comparator was placebo. ⁴

Recorded result: Total sleep time decreased by 24.5 minutes (P=.05; d=-.5).

In a randomized placebo-controlled crossover pilot trial involving 20 adults with DSM-5 insomnia disorder, researchers did not detect a difference in subjective sleep quality after an acute thc-cbd dose following 10 mg THC and 200 mg CBD once by the oral route over single study night. The recorded comparator was placebo. ⁴

Recorded result: No change in subjective sleep quality was detected.

In a randomized double-blind placebo-controlled parallel pilot trial involving 30 adults with primary moderate-to-severe insomnia, researchers did not detect a difference in self-reported sleep-onset latency following 150 mg nightly by the sublingual route over 2 weeks. The recorded comparator was placebo. ⁵

Recorded result: No between-treatment difference was detected throughout the trial (P>0.05).

In a randomized double-blind placebo-controlled parallel pilot trial involving 30 adults with primary moderate-to-severe insomnia, researchers did not detect a difference in self-reported sleep efficiency following 150 mg nightly by the sublingual route over 2 weeks. The recorded comparator was placebo. ⁵

Recorded result: No between-treatment difference was detected throughout the trial (P>0.05).

In a randomized double-blind placebo-controlled parallel pilot trial involving 30 adults with primary moderate-to-severe insomnia, researchers did not detect a difference in wake after sleep onset following 150 mg nightly by the sublingual route over 2 weeks. The recorded comparator was placebo. ⁵

Recorded result: No between-treatment difference was detected throughout the trial (P>0.05).

In a randomized double-blind placebo-controlled parallel pilot trial involving 30 adults with primary moderate-to-severe insomnia, researchers reported an increase in objective sleep efficiency following 150 mg nightly by the sublingual route over 2 weeks. The recorded comparator was placebo. ⁵

Recorded result: Mean difference 6.85 (standard error 2.95; P<0.05).

In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers did not detect a difference in wake after sleep onset following a single oral dose of 30 mg or 300 mg CBN. The recorded comparator was placebo. ⁶

In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers reported shorter sleep onset latency following 300 mg CBN. The recorded comparator was placebo. ⁶

In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers reported higher subjective sleep quality following 300 mg CBN. The recorded comparator was placebo. ⁶

In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers reported more NREM-2 sleep following 300 mg CBN. The recorded comparator was placebo. ⁶

In a randomized placebo-controlled crossover trial involving 64 patients with primary hypertension, researchers did not detect a difference in pittsburgh sleep quality index score in primary hypertension following 225 to 450 mg by the not stated in the PubMed abstract route over 5 weeks per condition. The recorded comparator was placebo. ⁷

Recorded result: No change in PSQI total score was detected (P=.862).

In a randomized double-blind placebo-controlled crossover pilot trial involving 20 adults with subthreshold insomnia symptoms, researchers reported an increase in sleep quality and efficiency after a THC-CBN-CBD-terpene supplement following one specified soft gel; schedule not stated in the abstract by the oral route over 10 days per condition. The recorded comparator was placebo. ⁸

Recorded result: The combination improved sleep quality/efficiency versus placebo (P<0.05).

In a randomized double-blind placebo-controlled crossover clinical trial involving 125 people with insomnia, researchers reported an increase in combined slow-wave and REM sleep percentage following 300 mg CBD plus 1 mg each of eight terpenes per administration by the oral route over 4 weeks. The recorded comparator was placebo. ⁹

Recorded result: Mean difference 1.3 percentage points (SE 0.60; 95% CI 0.1 to 2.5; P=0.03).

In a randomized double-blind placebo-controlled crossover clinical trial involving 125 people with insomnia, researchers did not detect a difference in total sleep time following 300 mg CBD plus 1 mg each of eight terpenes per administration by the oral route over 4 weeks. The recorded comparator was placebo. ⁹

Recorded result: The abstract reports no detected effect on total sleep time.

In a randomized placebo-controlled parallel study involving 28 healthy college-aged adults, researchers reported an increase in within-group questionnaire-rated sleep quality in healthy young adults following 50 mg daily by the oral route over 8 weeks. The recorded comparator was calorie-matched placebo. ¹⁰

Recorded result: The CBD group improved from baseline (P=0.0023); the abstract does not report a CBD-versus-placebo effect estimate for sleep quality.

In a randomized placebo-controlled parallel study involving 28 healthy college-aged adults, researchers did not detect a difference in sleep quantity in healthy young adults following 50 mg daily by the oral route over 8 weeks. The recorded comparator was calorie-matched placebo. ¹⁰

Recorded result: No significant CBD-versus-placebo difference in sleep quantity was detected.

In a systematic review and meta-analysis of medical cannabis for adult insomnia involving adults with insomnia across included studies, researchers reported an increase in sleep improvement attributed to 50-to-300-mg CBD doses in an insomnia review following CBD 50 to 300 mg in the favorable review conclusion by the oral or sublingual across included studies route over varied across included studies. The recorded comparator was varied across included studies. ¹¹

Recorded result: The abstract concluded that CBD doses of 50 to 300 mg were safe and effective for improving sleep; it did not report a CBD-specific pooled effect estimate.

In a double-blind randomized placebo-controlled parallel trial involving 63 adults with elevated trait worry, researchers did not detect a difference in sleep disturbance versus placebo in high trait worriers following 300 mg daily by the not stated in the PubMed abstract route over 2 weeks. The recorded comparator was placebo and 50 mg CBD. ¹²

Recorded result: The 300 mg group did not differ significantly from placebo (B=-0.32; P=.10; d=.07).